Physicians need to be aware of this newly described complication
Every year, thousands of Australians are prescribed bisphosphonates for the treatment of osteoporosis. They are highly effective agents, with numerous large clinical trials demonstrating a significant reduction in the risk of osteoporotic fractures as early as 6 months after commencement of therapy. Bisphosphonates such as risedronate, alendronate, etidronate, pamidronate and zoledronic acid have an excellent safety profile, although gastro-oesophageal irritation or transient flu-like symptoms may occur in patients receiving oral or intravenous bisphosphonates, respectively. Other side effects, such as renal impairment, uveitis and osteonecrosis of the jaw, have been described but are extremely rare.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.